|
|
Post by sportsrancho on Jun 20, 2018 9:08:00 GMT -5
|
|
|
|
Post by peppy on Jun 20, 2018 9:10:02 GMT -5
|
|
|
|
ADA
Jun 20, 2018 9:16:18 GMT -5
Post by mnkdfann on Jun 20, 2018 9:16:18 GMT -5
Why are you guys excited over a poster from the 67th ADA back in 2007?
|
|
|
|
Post by peppy on Jun 20, 2018 9:17:26 GMT -5
Why are you guys excited over a poster from the 67th ADA back in 2007? because my chain got yanked. Never mind. |
|
|
|
Post by #NoMoreNeedles on Jun 20, 2018 9:33:53 GMT -5
|
|
|
|
Post by kimi on Jun 20, 2018 9:39:08 GMT -5
Oral Presentations
4:30 p.m.-6:30 p.m.
(continued
5:00 p.m.-5:15 p.m.
348 -OR Improved Postprandial Blood Glucose (PPBG) Excursions with Technosphere Inhaled Insulin (TI) Compared with Aspart in T1D Patients—STAT Study HALIS K. AKTURK, JANET K. SNELL-BERGEON, AMANDA REWERS, LESLIE J. KLAFF, ANNE PETERS, BRUCE W. BODE, TIMOTHY S. BAILEY, SATISH K. GARG, Aurora ----------------------------------------------, MannKind Corporation Booth 403 MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products, based on its proprietary Technosphere ® technology platform, for people living with diseases such as diabetes and pulmonary arterial hypertension. MannKind is headquartered in Westlake Village, California. ---------------------------------------------- SUNDAY, JUNE 24, 2018
6:45 p.m.-9:45 p.m.
The Right Recipe for Achieving Postprandial Glucose Control—To Inhale or Inject?
Sponsored by Medscape
Supported by an educational grant from MannKind Corporation
This live, interactive symposium will guide participants through a comprehensive diabetes management, including
a detailed look at how inhaled insulin can be used to improve patient outcomes. The “
diabetic chef”
will prepare an
example meal in between sessions, walking guests through the recipe, ingredient selection, cooking tips, and more.
Location:
Hyatt Regency Orlando, Plaza International Ballroom D-G
Contact:
Robert Zorzi/E-mail: rzorzi@medscape.net
|
|
|
|
Post by mannmade on Jun 20, 2018 9:39:14 GMT -5
As the title page says... “Diabetes Break Throughs Happen Here.”
Go Mannkind! And Dr. K!!
|
|
|
|
Post by peppy on Jun 20, 2018 9:45:55 GMT -5
inappropriately I am sure, I have not seen these names in quite a while. 78th Scientific Sessions Educational Support This activity is supported, in part, by unrestricted educational grants from the following companies: Merck Merck/Pfizer Alliance The Leona M. and Harry B. Helmsley Charitable Trust
remember leona Helmsley, "The Queen of Mean" she left 20 million to her dog? |
|
|
|
Post by Clement on Jun 20, 2018 10:16:28 GMT -5
|
|
|
|
Post by peppy on Jun 20, 2018 10:35:36 GMT -5
these are the ones we are looking for.  /photo/1 |
|
|
|
Post by peppy on Jun 20, 2018 10:41:15 GMT -5
|
|
|
|
Post by peppy on Jun 20, 2018 10:51:10 GMT -5
Total and Severe Hypoglycemia Is Reduced with Use of Inhaled Technosphere Insulin (TI, Afrezza®) Relative to Insulin Aspart in Type 1 Diabetes View session detail plan.core-apps.com/tristar_ada18/abstract/5188446740e191fd289345d56a7a8720Author Block: LAWRENCE BLONDE, FRANK POMPILIO, SIMON R. BRUCE, MARSHALL L. GRANT, DAVID M. KENDALL, New Orleans, LA, Westlake Village, CA, San Diego, CA, Danbury, CT Hypoglycemia (HG) and fear of HG limit effective insulin therapy and contribute to suboptimal glycemic control. Ultra-short acting insulins reduce HG risk by providing their glucose-lowering effect early and reducing the risk of late postprandial HG. AFFINITY-1, a treat-to-target study in T1D on multiple daily injection therapy, demonstrated one such ultra-short acting insulin, TI (Afrezza®), was non-inferior to SC aspart in A1C reduction (Bode et al, Diabetes Care 2015). Consistent with its action profile, a lower rate of HG was observed in TI users overall, particularly in the 2-5 h post-meal interval and in those achieving target A1C<7%. In this post-hoc analysis of patients with reported A1C values at end of treatment, mean rates for all HG and severe HG obtained from combined SMBG and AE reporting were significantly lower with TI than with aspart (Figure). A negative binomial regression including treatment, region, type of basal insulin, and A1C at end of treatment yielded an LS-mean HG rate for patients on TI 26% lower than comparable patients on aspart across the entire A1C range (mean ratio:0.74, 95% CI: 0.68-0.81). TI’s rapid onset and ultra-short action provide insulin when needed at meals and between meals. This profile improves overall and prandial glucose control and, as demonstrated in AFFINITY-1, has the potential to reduce the risk of late post-meal HG.  |
|
|
|
Post by peppy on Jun 20, 2018 11:07:46 GMT -5
1017-P - Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM) with Technosphere Inhaled Insulin (TI) Compared with Insulin Aspart in T1D Patients—STAT Study plan.core-apps.com/tristar_ada18/abstract/76c84679a693fbf5baf0df14cd0010faSixty patients with T1D on multiple daily injections (MDI) were randomized in a multi-center study, stratified by A1c values (<8.5% or ≥ 8.5%) to the control arm using aspart (n=34) vs. TI group (n=26). Patients in the TI arm were advised to take extra inhalations at 1 and 2 hours after meals based on post-prandial blood glucose (PPBG) values. Baseline characteristics and FEV1 were similar. Using per protocol (PPT) analysis, we examined outcomes over the 4-week period using linear regression with repeated measures. The primary outcomes were TIR (70-180 mg/dL) and PPBG excursions. Compliance with TI was based on its use when indicated at 1- and 2-hour PPBG. Patients with at least 80% compliance were included in PPT (n=15). Seven TI patients were non-compliant; 2 dropped out of the study; and 2 did not have CGM data. CGM glucose patterns and TIR for a patient with 100% or with 56% compliant with TI are shown (Figures 1a and 1b). TIR was significantly higher in the TI-compliant group compared to control or TI-non-compliant groups (Figure 1c). PPBG was also significantly lower in the TI-compliant compared to the control group at 1- and 2-hours post-prandial but not at 3 and 4 hours. PPBG was significantly lower in the compliant vs. non-compliant TI group at all time points (Figure 1d). We conclude that TI improves TIR and PPBG values, if patients use additional inhalations as directed.  |
|
|
|
Post by akemp3000 on Jun 20, 2018 11:12:03 GMT -5
LOVE seeing the score 59 to 127 in favor of Afrezza!!!!!!!!!
|
|
|
|
Post by oldfishtowner on Jun 20, 2018 13:01:27 GMT -5
Looks like the follow-up doses of Afrezza were not optimized, i.e., not high enough dose to bring the BG down sufficiently, at least on the average. (See Figure 1d., TI Compliant bars)
|
|
